All In Biotech

Free tool

FAERS Monitor: Tasigna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022068 or its brand name (Tasigna, Nilotinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

29,425

Serious

21,731

74% of reports

Hospitalization

6,487

Death reported

5,641

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3,231
  • fatigue2,112
  • rash1,654
  • nausea1,546
  • headache1,494
  • dyspnoea1,395
  • pain1,344
  • diarrhoea1,222
  • drug ineffective1,210
  • malaise1,143
  • pruritus1,134
  • pyrexia1,134
  • arthralgia1,092
  • asthenia1,065
  • vomiting1,064

Reports by year received

View as table
YearReports
200710
2008254
2009340
2010450
2011955
20121,851
20131,549
20142,183
20152,111
20162,531
20171,984
20182,275
20192,686
20202,319
20212,175
20221,821
20231,545
20241,084
2025748
2026554

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,024,734 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rashSignal1,6542.72.61,827
deathSignal3,2312.72.63,553
pyrexiaSignal1,1342.32.2887
pruritusSignal1,1342.12.0674
astheniaSignal1,0652.01.9562
fatigue2,1121.91.9998
arthralgia1,0921.91.8456
malaise1,1431.91.8466
dyspnoea1,3951.81.7472
headache1,4941.71.6447
vomiting1,0641.61.5256
pain1,3441.61.5281
nausea1,5461.41.3180
diarrhoea1,2221.41.3116
drug ineffective1,2100.70.6232

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.